Reuters logo
Bayer seeks Japanese approval for Eylea injections
September 4, 2014 / 7:56 AM / 3 years ago

Bayer seeks Japanese approval for Eylea injections

FRANKFURT (Reuters) - Germany’s Bayer said it has submitted an application for Japanese marketing authorization of Eylea to treat patients with a buildup of fluid in the back of the eye caused by a blockage of veins in the retina.

It said a late-stage drug trial showed that more patients with such a condition - macular edema secondary to branch retinal vein occlusion (BRVO) - showed an improvement in their ability to see when treated with Eylea compared with laser.

Reporting by Maria Sheahan; Editing by Christoph Steitz

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below